Dany Y. Matar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Dany Y. Matar has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
- Dennis P. Orgill
Division of Plastic and Reconstructive Surgery, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA 02115, USA
7 shared publications - Adriana C. Panayi
Department of Oral and Maxillofacial Surgery, Charité—Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany
5 shared publications - Samuel Knoedler
Department of Plastic Surgery and Hand Surgery, TUM University Hospital Munich, Ismaninger Str. 22, 81675 Munich, Germany
5 shared publications - Gabriel Hundeshagen
BG Klinik Ludwigshafen, Department of Hand, Plastic, and Reconstructive Surgery, Burn Center at Heidelberg University, Ludwig-Guttmann-Str. 13, 67071, Ludwigshafen, Germany
4 shared publications - Mengfan Wu
Department of Plastic Surgery Peking University Shenzhen Hospital Shenzhen Guangdong People's Republic of China
4 shared publications Adriana C. Panayi
Department of Cranio‐Maxillofacial and Oral Surgery University Hospital Zurich, University of Zurich Zurich Switzerland
3 shared publications
Latest Publications
- 9 October 2026
- Published by Wiley in Microsurgery
- Vol. 46 (7)
Frailty as a Predictor of Outcomes After Fibula Free Flap for Head and Neck Reconstruction: A Multi‐Institutional Analysis Using the mFI ‐5
Background: Chronological age inadequately reflects physiologic vulnerability in older adults undergoing complex reconstruction. Frailty, quantified by the 5‐item Modified Frailty Index (mFI‐5), may better stratify perioperative risk in fibula free flap (FFF) reconstruction for head and neck defects, but its impact remains underdefined. Methods: A retrospective cohort study of 406 adults undergoing FFF reconstruction (ACS‐NSQIP, 2009–2023) evaluated the association between mFI‐5 and 30‐day postoperative outcomes. Multivariable logistic regression identified independent predictors of medical and surgical complications. Results: Higher mFI‐5 scores were associated with increased medical complications (14.1% mFI‐5 = 0 vs. 34.3% mFI‐5 = 2; p = 0.02), including pneumonia and myocardial infarction. mFI‐5 = 1 (aOR 1.84; 95% CI, 1.01–3.47) and mFI‐5 = 2 (aOR 3.45; 95% CI, 1.38–8.57) independently predicted medical complications; mFI‐5 = 2 also predicted surgical complications (aOR 2.27; 95% CI, 1.00–5.43). Conclusions: Frailty is a stronger predictor of postoperative morbidity than chronological age. Incorporating frailty assessment may enhance risk stratification and perioperative decision‐making.
- 9 October 2026
- Published by Wiley in Microsurgery
- Vol. 46 (7)
Frailty as a Predictor of Outcomes After Fibula Free Flap for Head and Neck Reconstruction: A Multi‐Institutional Analysis Using the mFI ‐5
Background: Chronological age inadequately reflects physiologic vulnerability in older adults undergoing complex reconstruction. Frailty, quantified by the 5‐item Modified Frailty Index (mFI‐5), may better stratify perioperative risk in fibula free flap (FFF) reconstruction for head and neck defects, but its impact remains underdefined. Methods: A retrospective cohort study of 406 adults undergoing FFF reconstruction (ACS‐NSQIP, 2009–2023) evaluated the association between mFI‐5 and 30‐day postoperative outcomes. Multivariable logistic regression identified independent predictors of medical and surgical complications. Results: Higher mFI‐5 scores were associated with increased medical complications (14.1% mFI‐5 = 0 vs. 34.3% mFI‐5 = 2; p = 0.02), including pneumonia and myocardial infarction. mFI‐5 = 1 (aOR 1.84; 95% CI, 1.01–3.47) and mFI‐5 = 2 (aOR 3.45; 95% CI, 1.38–8.57) independently predicted medical complications; mFI‐5 = 2 also predicted surgical complications (aOR 2.27; 95% CI, 1.00–5.43). Conclusions: Frailty is a stronger predictor of postoperative morbidity than chronological age. Incorporating frailty assessment may enhance risk stratification and perioperative decision‐making.
Iron‐Based Metal‐Organic Framework MIL‐100(Fe) Regulates Keloid Scarring in a Humanized Keloid Model
Keloids are characterized by excessive collagen deposition and persistent inflammation, causing high morbidity and recurrence with limited effective treatments. In this study, MIL‐100(Fe)– a metal‐organic framework composed of ferrous/ferric ion nodes and 1,3,5‐benzenetricarboxylate ligands– is synthesized via a microwave‐assisted hydrothermal method and demonstrated nanoscale particle size (141.7 nm). In vitro, human keloid fibroblasts maintained >90% viability after 48 h with MIL‐100(Fe) treatment and showed robust cellular uptake within 2 h, compared to PBS‐treated controls. MIL‐100(Fe) significantly reduced fibroblast migration and downregulated fibrosis‐associated proteins after 48 h, including collagen I, collagen III, transforming growth factor beta 1 (TGF‐β1), SMAD3, and prolyl 4‐hydroxylase subunit alpha 1 (P4HA1). Western blot analysis confirmed that TGF‐β1 expression is more strongly suppressed in human keloid fibroblasts than in human monocytes. In an in vivo humanized keloid mouse model, four weeks of intralesional MIL‐100(Fe) injection reduced fibrous tissue volume by 27% by week two post‐treatment compared with controls. Histological analysis showed decreased fibroblast density, decreased collagen fiber area, polarized macrophage infiltration, and vacuolization in the MIL‐100(Fe) treated group. These findings suggest that MIL‐100(Fe) selectively targets the TGF‐β/SMAD pathway, thereby reducing collagen deposition and fibrosis, and highlight its potential as a therapeutic nanoplatform for keloid treatment.
Iron‐Based Metal‐Organic Framework MIL‐100(Fe) Regulates Keloid Scarring in a Humanized Keloid Model
Keloids are characterized by excessive collagen deposition and persistent inflammation, causing high morbidity and recurrence with limited effective treatments. In this study, MIL‐100(Fe)– a metal‐organic framework composed of ferrous/ferric ion nodes and 1,3,5‐benzenetricarboxylate ligands– is synthesized via a microwave‐assisted hydrothermal method and demonstrated nanoscale particle size (141.7 nm). In vitro, human keloid fibroblasts maintained >90% viability after 48 h with MIL‐100(Fe) treatment and showed robust cellular uptake within 2 h, compared to PBS‐treated controls. MIL‐100(Fe) significantly reduced fibroblast migration and downregulated fibrosis‐associated proteins after 48 h, including collagen I, collagen III, transforming growth factor beta 1 (TGF‐β1), SMAD3, and prolyl 4‐hydroxylase subunit alpha 1 (P4HA1). Western blot analysis confirmed that TGF‐β1 expression is more strongly suppressed in human keloid fibroblasts than in human monocytes. In an in vivo humanized keloid mouse model, four weeks of intralesional MIL‐100(Fe) injection reduced fibrous tissue volume by 27% by week two post‐treatment compared with controls. Histological analysis showed decreased fibroblast density, decreased collagen fiber area, polarized macrophage infiltration, and vacuolization in the MIL‐100(Fe) treated group. These findings suggest that MIL‐100(Fe) selectively targets the TGF‐β/SMAD pathway, thereby reducing collagen deposition and fibrosis, and highlight its potential as a therapeutic nanoplatform for keloid treatment.
- 1 October 2025
- Published by Elsevier in Journal of Stomatology Oral and Maxillofacial Surgery
- Vol. 127 (1) , 102584
Artificial intelligence outperforms a nomogram for osteoradionecrosis prognostication following fibula free flap reconstruction in oral cancer patients
- 1 October 2025
- Published by Elsevier in Journal of Stomatology Oral and Maxillofacial Surgery
- Vol. 127 (1) , 102584
Artificial intelligence outperforms a nomogram for osteoradionecrosis prognostication following fibula free flap reconstruction in oral cancer patients
- 7 May 2025
- Published by SAGE Publications in Advances in Wound Care
- Vol. 15 (6) , 355-369
An Adipose-Derived Stem Cell Exosome Sheet Promotes Oral Mucosal Wound Healing
Objective: Oral mucosal wound healing is not completely understood, and effective therapies are lacking. This study explores the potential of an adipose-derived stem cell (ADSC) exosome sheet in enhancing intraoral wound healing in rats. Approach: An ADSC exosome sheet derived from Tisseel and rat adipose tissue (ADSC-exo) was applied to 16 rats with 6 mm full-thickness mucosal hard palate wounds. Eight wounds received ADSC-exo with a superficial occlusive dressing (ADSC-exo group), and eight received only an occlusive dressing (control group). Wound closure was monitored on days 0, 2, 4, 7, and 10, with dressings changed every 2 days. On day 10, rats were sacrificed, and wounds ( n = 8 per group) were collected for immunohistochemical analysis. In vitro , four ADSC-exosome concentrations (0, 4.5 × 10 11 , 9 × 10 11 , and 18 × 10 11 exosomes/mL; n = 4 per group) were applied to rat oral mucosal fibroblasts to assess migration speed. Results: ADSC-exo accelerated wound closure (18% ± 5% vs. 35% ± 9% of initial wound area; p = 0.002) and fibroblast migration (for 18 × 10 11 exosomes/mL at 24 h: 29.7% ± 3% vs. 62.2% ± 4% of initial gap area; p < 0.0001) compared with the control. ADSC-exo promoted reepithelialization (87% ± 14% vs. 21% ± 6%; p < 0.0001), proliferation (34 ± 12 vs. 18 ± 7 Ki67+/high-power field [HPF]; p = 0.004), and neovascularization (28 ± 9 vs. 11 ± 5 CD31+/HPF; p = 0.0002) while reducing inflammation (4 ± 1 vs. 13 ± 9 CD68+/HPF; p < 0.0001) and increasing M2 macrophages (9.2 ± 2 vs. 4.2 ± 3 CD163+/HPF; p = 0.0008). ADSC-exo increased Transforming Growth Factor beta 1 (TGF-β1) (1.3 ± 0.3 vs. 0.9 ± 0.2; p = 0.006), Smad3 (0.9 ± 0.02 vs. 0.7 ± 0.1; p = 0.006), and collagen I (1.5 ± 0.9 vs. 0.5 ± 0.3; p = 0.005) while downregulating caspase-3 (0.7 ± 0.3 vs. 1.1 ± 0.2; p = 0.003) and Bax (0.9 ± 0.2 vs. 1.4 ± 0.1; p < 0.0001). Innovation: This is the first study to demonstrate the pro-wound healing effects of an ADSC exosome sheet on intraoral wounds. This paves the way for future research and clinical applications of ADSC exosomes in mucosal wound healing. Conclusions: Application of an ADSC-exo to rat mucosal wounds significantly improved wound healing. Mechanistically, these effects may be linked to upregulated activity of the TGF-β/Smad pathway.
- 7 May 2025
- Published by SAGE Publications in Advances in Wound Care
- Vol. 15 (6) , 355-369
An Adipose-Derived Stem Cell Exosome Sheet Promotes Oral Mucosal Wound Healing
Objective: Oral mucosal wound healing is not completely understood, and effective therapies are lacking. This study explores the potential of an adipose-derived stem cell (ADSC) exosome sheet in enhancing intraoral wound healing in rats. Approach: An ADSC exosome sheet derived from Tisseel and rat adipose tissue (ADSC-exo) was applied to 16 rats with 6 mm full-thickness mucosal hard palate wounds. Eight wounds received ADSC-exo with a superficial occlusive dressing (ADSC-exo group), and eight received only an occlusive dressing (control group). Wound closure was monitored on days 0, 2, 4, 7, and 10, with dressings changed every 2 days. On day 10, rats were sacrificed, and wounds ( n = 8 per group) were collected for immunohistochemical analysis. In vitro , four ADSC-exosome concentrations (0, 4.5 × 10 11 , 9 × 10 11 , and 18 × 10 11 exosomes/mL; n = 4 per group) were applied to rat oral mucosal fibroblasts to assess migration speed. Results: ADSC-exo accelerated wound closure (18% ± 5% vs. 35% ± 9% of initial wound area; p = 0.002) and fibroblast migration (for 18 × 10 11 exosomes/mL at 24 h: 29.7% ± 3% vs. 62.2% ± 4% of initial gap area; p < 0.0001) compared with the control. ADSC-exo promoted reepithelialization (87% ± 14% vs. 21% ± 6%; p < 0.0001), proliferation (34 ± 12 vs. 18 ± 7 Ki67+/high-power field [HPF]; p = 0.004), and neovascularization (28 ± 9 vs. 11 ± 5 CD31+/HPF; p = 0.0002) while reducing inflammation (4 ± 1 vs. 13 ± 9 CD68+/HPF; p < 0.0001) and increasing M2 macrophages (9.2 ± 2 vs. 4.2 ± 3 CD163+/HPF; p = 0.0008). ADSC-exo increased Transforming Growth Factor beta 1 (TGF-β1) (1.3 ± 0.3 vs. 0.9 ± 0.2; p = 0.006), Smad3 (0.9 ± 0.02 vs. 0.7 ± 0.1; p = 0.006), and collagen I (1.5 ± 0.9 vs. 0.5 ± 0.3; p = 0.005) while downregulating caspase-3 (0.7 ± 0.3 vs. 1.1 ± 0.2; p = 0.003) and Bax (0.9 ± 0.2 vs. 1.4 ± 0.1; p < 0.0001). Innovation: This is the first study to demonstrate the pro-wound healing effects of an ADSC exosome sheet on intraoral wounds. This paves the way for future research and clinical applications of ADSC exosomes in mucosal wound healing. Conclusions: Application of an ADSC-exo to rat mucosal wounds significantly improved wound healing. Mechanistically, these effects may be linked to upregulated activity of the TGF-β/Smad pathway.
- 31 May 2024
- Published by Elsevier in Journal of Plastic, Reconstructive & Aesthetic Surgery
- Vol. 96, 13-22
A nomogram for predicting outcomes following pedicled flap reconstruction of the lower extremity
- 31 May 2024
- Published by Elsevier in Journal of Plastic, Reconstructive & Aesthetic Surgery
- Vol. 96, 13-22
A nomogram for predicting outcomes following pedicled flap reconstruction of the lower extremity
- Open Access
- 5 April 2024
- Published by Elsevier in JPRAS Open
- Vol. 40, 360-374
Similarity of Seroma Rate at the Medial Thigh following Free Flap Harvesting or Medial Thigh Lift: A Systematic Review and Meta-analysis
- 5 April 2024
- Published by Elsevier in JPRAS Open
- Vol. 40, 360-374
Open AccessSimilarity of Seroma Rate at the Medial Thigh following Free Flap Harvesting or Medial Thigh Lift: A Systematic Review and Meta-analysis
- Top Cited PapersOpen Access
- 7 September 2023
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 109 (12) , 4238-4262
Impact of sarcopenia on outcomes in surgical patients: a systematic review and meta-analysis
Background: Surgeons have historically used age as a preoperative predictor of postoperative outcomes. Sarcopenia, the loss of skeletal muscle mass due to disease or biological age, has been proposed as a more accurate risk predictor. The prognostic value of sarcopenia assessment in surgical patients remains poorly understood. Therefore, the authors aimed to synthesize the available literature and investigate the impact of sarcopenia on perioperative and postoperative outcomes across all surgical specialties. Methods: The authors systematically assessed the prognostic value of sarcopenia on postoperative outcomes by conducting a systematic review and meta-analysis according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, searching the PubMed/MEDLINE and EMBASE databases from inception to 1st October 2022. Their primary outcomes were complication occurrence, mortality, length of operation and hospital stay, discharge to home, and postdischarge survival rate at 1, 3, and 5 years. Subgroup analysis was performed by stratifying complications according to the Clavien–Dindo classification system. Sensitivity analysis was performed by focusing on studies with an oncological, cardiovascular, emergency, or transplant surgery population and on those of higher quality or prospective study design. Results: A total of 294 studies comprising 97 643 patients, of which 33 070 had sarcopenia, were included in our analysis. Sarcopenia was associated with significantly poorer postoperative outcomes, including greater mortality, complication occurrence, length of hospital stay, and lower rates of discharge to home (all PPPPP=0.03 and P=0.04, respectively) patients with sarcopenia. In the transplant surgery cohort, mortality was significantly higher in patients with sarcopenia (PP=0.007). Sensitivity analysis based on higher quality studies and prospective studies showed that sarcopenia remained a significant predictor of mortality and complication occurrence (all P<0.00001). Conclusion: Sarcopenia is a significant predictor of poorer outcomes in surgical patients. Preoperative assessment of sarcopenia can help surgeons identify patients at risk, critically balance eligibility, and refine perioperative management. Large-scale studies are required to further validate the importance of sarcopenia as a prognostic indicator of perioperative risk, especially in surgical subspecialties.
- 7 September 2023
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 109 (12) , 4238-4262
Top Cited PapersOpen AccessImpact of sarcopenia on outcomes in surgical patients: a systematic review and meta-analysis
Background: Surgeons have historically used age as a preoperative predictor of postoperative outcomes. Sarcopenia, the loss of skeletal muscle mass due to disease or biological age, has been proposed as a more accurate risk predictor. The prognostic value of sarcopenia assessment in surgical patients remains poorly understood. Therefore, the authors aimed to synthesize the available literature and investigate the impact of sarcopenia on perioperative and postoperative outcomes across all surgical specialties. Methods: The authors systematically assessed the prognostic value of sarcopenia on postoperative outcomes by conducting a systematic review and meta-analysis according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, searching the PubMed/MEDLINE and EMBASE databases from inception to 1st October 2022. Their primary outcomes were complication occurrence, mortality, length of operation and hospital stay, discharge to home, and postdischarge survival rate at 1, 3, and 5 years. Subgroup analysis was performed by stratifying complications according to the Clavien–Dindo classification system. Sensitivity analysis was performed by focusing on studies with an oncological, cardiovascular, emergency, or transplant surgery population and on those of higher quality or prospective study design. Results: A total of 294 studies comprising 97 643 patients, of which 33 070 had sarcopenia, were included in our analysis. Sarcopenia was associated with significantly poorer postoperative outcomes, including greater mortality, complication occurrence, length of hospital stay, and lower rates of discharge to home (all PPPPP=0.03 and P=0.04, respectively) patients with sarcopenia. In the transplant surgery cohort, mortality was significantly higher in patients with sarcopenia (PP=0.007). Sensitivity analysis based on higher quality studies and prospective studies showed that sarcopenia remained a significant predictor of mortality and complication occurrence (all P<0.00001). Conclusion: Sarcopenia is a significant predictor of poorer outcomes in surgical patients. Preoperative assessment of sarcopenia can help surgeons identify patients at risk, critically balance eligibility, and refine perioperative management. Large-scale studies are required to further validate the importance of sarcopenia as a prognostic indicator of perioperative risk, especially in surgical subspecialties.
- Open Access
- 11 February 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (4) , 1444
Early Outcomes and Risk Factors in Orthognathic Surgery for Mandibular and Maxillary Hypo- and Hyperplasia: A 13-Year Analysis of a Multi-Institutional Database
Background: Orthognathic surgery (OS) is a frequently performed procedure for the correction of dentofacial deformities and malocclusion. Research on OS is mostly limited to single-surgeon experience or single-institutional reports. We, therefore, retrospectively analyzed a multi-institutional database to investigate outcomes of OS and identify risk factors for peri- and postoperative complications. Methods: We reviewed the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) database (2008–2020) to identify patients who underwent OS for mandibular and maxillary hypo- and hyperplasia. The postoperative outcomes of interest included 30-day surgical and medical complications, reoperation, readmission, and mortality. We also evaluated risk factors for complications. Results: The study population included 674 patients, 48% of whom underwent single jaw surgery, 40% double jaw surgery, and 5.5% triple jaw surgery. The average age was 29 ± 11 years, with an equal gender distribution (females: n = 336; 50%, males: n = 338; 50%). Adverse events were relatively rare, with a total of 29 (4.3%) complications reported. The most common surgical complication was superficial incisional infection (n = 14; 2.1%). While the multivariable analysis revealed isolated single lower jaw surgery (p = 0.03) to be independently associated with surgical complication occurrence, it also identified an association between the outpatient setting and the frequency of surgical complications (p = 0.03) and readmissions (p = 0.02). In addition, Asian ethnicity was identified as a risk factor for bleeding (p = 0.003) and readmission (p = 0.0009). Conclusion: Based on the information recorded by the ACS-NSQIP database, our analysis underscored the positive (short-term) safety profile of OS. We found OS of the mandible to be associated with higher complication rates. The calculated risk role of OS in the outpatient setting warrants further investigation. A significant correlation between Asian OS patients and postoperative adverse events was found. Implementation of these novel risk factors into the surgical workflow may help facial surgeons refine their patient selection and improve patient outcomes. Future studies are needed to investigate the causal relationships of the observed statistical correlations.
- 11 February 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (4) , 1444
Open AccessEarly Outcomes and Risk Factors in Orthognathic Surgery for Mandibular and Maxillary Hypo- and Hyperplasia: A 13-Year Analysis of a Multi-Institutional Database
Background: Orthognathic surgery (OS) is a frequently performed procedure for the correction of dentofacial deformities and malocclusion. Research on OS is mostly limited to single-surgeon experience or single-institutional reports. We, therefore, retrospectively analyzed a multi-institutional database to investigate outcomes of OS and identify risk factors for peri- and postoperative complications. Methods: We reviewed the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) database (2008–2020) to identify patients who underwent OS for mandibular and maxillary hypo- and hyperplasia. The postoperative outcomes of interest included 30-day surgical and medical complications, reoperation, readmission, and mortality. We also evaluated risk factors for complications. Results: The study population included 674 patients, 48% of whom underwent single jaw surgery, 40% double jaw surgery, and 5.5% triple jaw surgery. The average age was 29 ± 11 years, with an equal gender distribution (females: n = 336; 50%, males: n = 338; 50%). Adverse events were relatively rare, with a total of 29 (4.3%) complications reported. The most common surgical complication was superficial incisional infection (n = 14; 2.1%). While the multivariable analysis revealed isolated single lower jaw surgery (p = 0.03) to be independently associated with surgical complication occurrence, it also identified an association between the outpatient setting and the frequency of surgical complications (p = 0.03) and readmissions (p = 0.02). In addition, Asian ethnicity was identified as a risk factor for bleeding (p = 0.003) and readmission (p = 0.0009). Conclusion: Based on the information recorded by the ACS-NSQIP database, our analysis underscored the positive (short-term) safety profile of OS. We found OS of the mandible to be associated with higher complication rates. The calculated risk role of OS in the outpatient setting warrants further investigation. A significant correlation between Asian OS patients and postoperative adverse events was found. Implementation of these novel risk factors into the surgical workflow may help facial surgeons refine their patient selection and improve patient outcomes. Future studies are needed to investigate the causal relationships of the observed statistical correlations.
- 7 October 2022
- Published by IOP Publishing in Biomedical Materials
- Vol. 17 (6) , 065014
Xenogenic induction of adipose tissue and maintenance through pre- and post-conditioning using external volume expansion
External volume expansion (EVE) has been shown to improve fat graft survival. In this study, we investigated the xenogenic implantation of human allograft adipose matrix (AAM) in non-immunocompromised mice in combination with pre- and post-conditioning with EVE to assess long-term adipose tissue survival. Sixty-eight recipient sites in thirty-four eight-week-old wild type (C57BL/6J) mice were separated into four groups. Thirty-four sites received no conditioning and either a subcutaneous injection of 300 μl saline ( n = 17; PBS group) or AAM ( n = 17; AAM group). Thirty-four sites received pre-conditioning with EVE (Day -7–3 pre-grafting) and 300 μl of AAM. Seventeen of these sites received immediate post-conditioning (Day 1–5 post-grafting) and 17 delayed post-conditioning (Day 28–32 post-grafting). Tissue was harvested at week 12 for analysis. At 12 weeks, immediate and delayed post-conditioning enabled higher volume retention ( p = 0.02 and p < 0.0001, respectively). Adipose Stem Cells were greater in the AAM+Del-EVE group compared to the AAM ( p = 0.01). Microvessel density was lower in the AAM group compared to the AAM+Imm-EVE ( p = 0.04) and AAM+Del-EVE group ( p = 0.02). Macrophage infiltration was lower in the AAM+Imm-EVE ( p = 0.002) and AAM+Del-EVE ( p = 0.003) groups compared to the AAM group. PCR analysis and Western blotting identified a significantly higher expression of PPAR- γ , LPL and VEGF with delayed-conditioning. Pre- and post-conditioning, particularly delayed-post-conditioning, of the recipient site optimized the microenvironment allowing significant adipogenesis and survival of neo-adipose tissue through robust angiogenesis. This study supports that xenogenic transplantation of adipose matrix allows adipose tissue formation and survival with EVE as an adjuvant.
- 7 October 2022
- Published by IOP Publishing in Biomedical Materials
- Vol. 17 (6) , 065014
Xenogenic induction of adipose tissue and maintenance through pre- and post-conditioning using external volume expansion
External volume expansion (EVE) has been shown to improve fat graft survival. In this study, we investigated the xenogenic implantation of human allograft adipose matrix (AAM) in non-immunocompromised mice in combination with pre- and post-conditioning with EVE to assess long-term adipose tissue survival. Sixty-eight recipient sites in thirty-four eight-week-old wild type (C57BL/6J) mice were separated into four groups. Thirty-four sites received no conditioning and either a subcutaneous injection of 300 μl saline ( n = 17; PBS group) or AAM ( n = 17; AAM group). Thirty-four sites received pre-conditioning with EVE (Day -7–3 pre-grafting) and 300 μl of AAM. Seventeen of these sites received immediate post-conditioning (Day 1–5 post-grafting) and 17 delayed post-conditioning (Day 28–32 post-grafting). Tissue was harvested at week 12 for analysis. At 12 weeks, immediate and delayed post-conditioning enabled higher volume retention ( p = 0.02 and p < 0.0001, respectively). Adipose Stem Cells were greater in the AAM+Del-EVE group compared to the AAM ( p = 0.01). Microvessel density was lower in the AAM group compared to the AAM+Imm-EVE ( p = 0.04) and AAM+Del-EVE group ( p = 0.02). Macrophage infiltration was lower in the AAM+Imm-EVE ( p = 0.002) and AAM+Del-EVE ( p = 0.003) groups compared to the AAM group. PCR analysis and Western blotting identified a significantly higher expression of PPAR- γ , LPL and VEGF with delayed-conditioning. Pre- and post-conditioning, particularly delayed-post-conditioning, of the recipient site optimized the microenvironment allowing significant adipogenesis and survival of neo-adipose tissue through robust angiogenesis. This study supports that xenogenic transplantation of adipose matrix allows adipose tissue formation and survival with EVE as an adjuvant.
- Open Access
- 6 October 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (10) , 2125
Continuous NPWT Regulates Fibrosis in Murine Diabetic Wound Healing
Scarring is associated with significant morbidity. The mechanical signaling factor yes-associated protein (YAP) has been linked to Engrailed-1 (En1)-lineage positive fibroblasts (EPFs), a pro-scarring fibroblast lineage, establishing a connection between mechanotransduction and fibrosis. In this study, we investigate the impact of micromechanical forces exerted through negative pressure wound therapy (NPWT) on the pathophysiology of fibrosis. Full-thickness excisional dorsal skin wounds were created on diabetic (db/db) mice which were treated with occlusive covering (control) or NPWT (continuous, −125 mmHg, 7 days; NPWT). Analysis was performed on tissue harvested 10 days after wounding. NPWT was associated with increased YAP (p = 0.04) but decreased En1 (p = 0.0001) and CD26 (p < 0.0001). The pro-fibrotic factors Vimentin (p = 0.04), α-SMA (p = 0.04) and HSP47 (p = 0.0008) were decreased with NPWT. Fibronectin was higher (p = 0.01) and collagen deposition lower in the NPWT group (p = 0.02). NPWT increased cellular proliferation (p = 0.002) and decreased apoptosis (p = 0.03). Western blotting demonstrated increased YAP (p = 0.02) and RhoA (p = 0.03) and decreased Caspase-3 (p = 0.03) with NPWT. NPWT uncouples YAP from EPF activation, through downregulation of Caspace-3, a pro-apoptotic factor linked to keloid formation. Mechanotransduction decreases multiple pro-fibrotic factors. Through this multifactorial process, NPWT significantly decreases fibrosis and offers promising potential as a mode to improve scar appearance.
- 6 October 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (10) , 2125
Open AccessContinuous NPWT Regulates Fibrosis in Murine Diabetic Wound Healing
Scarring is associated with significant morbidity. The mechanical signaling factor yes-associated protein (YAP) has been linked to Engrailed-1 (En1)-lineage positive fibroblasts (EPFs), a pro-scarring fibroblast lineage, establishing a connection between mechanotransduction and fibrosis. In this study, we investigate the impact of micromechanical forces exerted through negative pressure wound therapy (NPWT) on the pathophysiology of fibrosis. Full-thickness excisional dorsal skin wounds were created on diabetic (db/db) mice which were treated with occlusive covering (control) or NPWT (continuous, −125 mmHg, 7 days; NPWT). Analysis was performed on tissue harvested 10 days after wounding. NPWT was associated with increased YAP (p = 0.04) but decreased En1 (p = 0.0001) and CD26 (p < 0.0001). The pro-fibrotic factors Vimentin (p = 0.04), α-SMA (p = 0.04) and HSP47 (p = 0.0008) were decreased with NPWT. Fibronectin was higher (p = 0.01) and collagen deposition lower in the NPWT group (p = 0.02). NPWT increased cellular proliferation (p = 0.002) and decreased apoptosis (p = 0.03). Western blotting demonstrated increased YAP (p = 0.02) and RhoA (p = 0.03) and decreased Caspase-3 (p = 0.03) with NPWT. NPWT uncouples YAP from EPF activation, through downregulation of Caspace-3, a pro-apoptotic factor linked to keloid formation. Mechanotransduction decreases multiple pro-fibrotic factors. Through this multifactorial process, NPWT significantly decreases fibrosis and offers promising potential as a mode to improve scar appearance.